Sugi Predict

Sugi Predict / Compounds / SCHEMBL3498202

SCHEMBL3498202

SCHEMBL3498202

CCOC(=O)C1CN(C(=O)OC(C)(C)C)CCO1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ PDK1 Q15118 2/20 0.46
▸ RECQL P46063 2/20 0.43
▸ TSHR P16473 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ NR1H2 P55055 1/20 0.40
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23107346 0.90 SMN1; SMN2 (0.46) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL14050904 0.85 USP2 (0.43) USP2SMN1; SMN2PDK1RECQLTSHR
SCHEMBL25062267 0.85 SMN1; SMN2 (0.43) USP2SMN1; SMN2PDK1RECQLTSHR
SCHEMBL1439935 0.85 PDK1 (0.59) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL25630738 0.85 PDK1 (0.59) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL14971339 0.83 USP2 (0.50) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL26966235 0.83 SMN1; SMN2 (0.44) USP2SMN1; SMN2RECQLTSHRALDH1A1
SCHEMBL26966246 0.83 SMN1; SMN2 (0.44) USP2SMN1; SMN2RECQLTSHRALDH1A1
SCHEMBL26966376 0.83 SMN1; SMN2 (0.44) USP2SMN1; SMN2RECQLTSHRALDH1A1
SCHEMBL194710 0.81 USP2 (0.54) USP2SMN1; SMN2PDK1RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747239-A1 SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2026-05-27 — — EP disclosed
CN-122079960-A Alkynyl quinazoline compounds — 2026-05-26 — — CN disclosed
EP-4013749-B1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-03-11 — — EP disclosed
US-20260062420-A1 NOVEL DPP1 INHIBITORS AND USES THEREOF INSMED INC (US) 2026-03-05 — — US disclosed
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-19 — — US disclosed
US-12435046-B2 Alkynyl quinazoline compounds BLACK DIAMOND THERAPEUTICS, INC. (US) 2025-10-07 — — US disclosed
EP-4561565-A2 NOVEL DPP1 INHIBITORS AND USES THEREOF Insmed Incorporated (US) 2025-06-04 — — EP disclosed
CN-119390683-A Alkynyl quinazoline compounds 黑钻治疗公司 2025-02-07 — — CN disclosed
WO-2025019823-A1 SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT MERCK SHARP & DOHME LLC (US) 2025-01-23 — — WO disclosed
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-07-11 — — US disclosed
US-7442795-B2 Triazole compounds useful in therapy PFIZER INC. (US) 2008-10-28 — — US disclosed
US-7442795-B2 Triazole compounds useful in therapy PFIZER INC. (US) 2008-10-28 — — US disclosed
US-7442795-B2 Triazole compounds useful in therapy PFIZER INC. (US) 2008-10-28 — — US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 — — EP disclosed
EP-1597260-B1 TRIAZOLE COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2006-12-27 — — EP disclosed
US-7119088-B2 Triazole compounds useful in therapy PFIZER INC. (US) 2006-10-10 — — US disclosed
US-20060194794-A1 Triazole compounds useful in therapy PFIZER INC 2006-08-31 — — US disclosed
CN-1751047-A Triazole compounds useful in therapy PFIZER (US) 2006-03-22 — — CN disclosed
US-20040186091-A1 A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis PFIZER INC 2004-09-23 — — US disclosed
WO-2004074291-A1 TRIAZOLE COMPOUNDS USEFUL IN THERAPY PFIZER LIMITED (GB) 2004-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435046-B2 Alkynyl quinazoline compounds GLS, GLS2, MCL1 USP2 2868/4885SMN1; SMN2 206/4885PDK1 434/4885
US-20060194794-A1 Triazole compounds useful in therapy CYP3A43, CYP3A5, CYP3A7 USP2 3742/4885SMN1; SMN2 4216/4885PDK1 1633/4885
US-20040186091-A1 A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis CNR1, NR1H2, OXER1 USP2 2607/4885SMN1; SMN2 1338/4885PDK1 3435/4885
US-20260062420-A1 NOVEL DPP1 INHIBITORS AND USES THEREOF DPP4, DPP3, DPP7 USP2 1293/4885SMN1; SMN2 895/4885PDK1 1358/4885
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 USP2 3743/4885SMN1; SMN2 793/4885PDK1 2445/4885
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF LRRK2, PINK1, PARK7 USP2 2538/4885SMN1; SMN2 778/4885PDK1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.